Molecular and Cellular Biochemistry

, Volume 132, Issue 1, pp 69–80 | Cite as

Modification of myosin isozymes and SR Ca2+-pump ATPase of the diabetic rat heart by lipid-lowering interventions

  • Heinz Rupp
  • Vijayan Elimban
  • Naranjan S. Dhalla


To define metabolic influences on cardiac myosin expression and sarcoplasmic reticulum (SR) Ca2+-stimulated ATPase streptozotocin-diabetic rats were treated for 9–10 wk with etomoxir, an inhibitor of carnitine palmitoyl transferase I (CPT-1) and fatty acid synthesis, or an antilipolytic drug, acipimox. Etomoxir reduced myosin V3 of diabetic rats but did not normalize it. However, the high serum triglyceride, free-fatty acid and cholesterol concentrations in diabetic animals were greatly reduced. After bypassing the CPT-1 inhibition with a medium-chain fatty acid (miglyol) diet, the V3 contents and serum lipids were still reduced in the etomoxir-treated diabetic rats; V3 was also reduced in diabetic rats fed miglyol or treated with acipimox. Since low serum insulin or triiodothyronine concentrations in diabetic rats were not improved by these interventions but changes in V3 were correlated with those in triglyceride, free-fatty acid and cholesterol concentrations, it is likely that myosin may be influenced by some metabolic factors. To assess the role of adrenergic influences, diabetic rats (7–8 wk) were treated with an antisympathotonic drug, moxonidine, a β-adrenoceptor blocking drug, propranolol, and a bradycardic drug, tedisamil. Myosin V3 was not reduced significantly in moxonidine-treated or propranolol-treated rats in comparison to untreated diabetic rats. Serum thyroid hormones and insulin were not altered, whereas triglycerides were reduced but not significantly by these antiadrenergic agents. Lowering serum lipids in diabetic rats by treatment with etomoxir, miglyol and acipimox increased the depressed SR Ca2+-stimulated ATPase activity. On the other hand, in diabetic rats treated with moxonidine, propranolol or tedisamil, the ATPase activity was not increased significantly. These results suggest that normalization of blood lipids is important for improving subcellular organelle function in diabetic hearts with impaired glucose utilization.

Key words

diabetic heart myosin isozymes sarcoplasmic reticulum Ca2+-stimulated ATPase blood lipids 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nagano M, Dhalla NS: The Diabetic Heart Raven Press, New York, 1991Google Scholar
  2. 2.
    Dillmann WH: Diabetes mellitus induces changes in cardiac myosin of the rat. Diabetes 29:579–582, 1980Google Scholar
  3. 3.
    Rupp H, Elimban V, Dhalla NS: Diabetes-like action of intermittent fasting on sarcoplasmic reticulum Ca2+-pump ATPase and myosin isoenzymes can be prevented by sucrose. Biochem Biophys Res Commun 164:319–325, 1989Google Scholar
  4. 4.
    Ganguly PK, Pierce GN, Dhalla KS, Dhalla NS: Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am J Physiol 244:E528-E535, 1983Google Scholar
  5. 5.
    Morkin E, Bahl JJ, Markham BE: Control of cardiac myosin heavy chain gene expression by thyroid hormones. In: LH Kedes, FE Stockdale (eds) Cellular and Molecular Biology of Muscle Development. Alan R. Liss, New York, 1989, pp 381–389Google Scholar
  6. 6.
    Dillmann WH: Influence of thyroid hormone administration on myosin ATPase activity and myosin isoenzyme distribution in the heart of diabetic rats. Metabolism 31:199–204, 1982Google Scholar
  7. 7.
    Ganguly PK, Dhalla KS, Innes IR, Beamish RE, Dhalla NS: Altered norepinephrine turnover and metabolism in diabetic cardiomyopathy. Circ Res 59:684–693, 1986Google Scholar
  8. 8.
    Ernsberger P, Damon TH, Graff LM, Schäfer SG, Christen MO: Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. J Pharmacol Exp Ther 264: 172–182, 1993Google Scholar
  9. 9.
    Ollivier JP, Christen MO, Schäfer SG: Moxonidine: a second generation of centrally acting drugs. An appraisal of clinical experience. J Cardiovasc Pharmacol 20 (suppl 4):S31-S36, 1992Google Scholar
  10. 10.
    Presta E, Leibel RL, Hirsch J: Regional changes in adrenergic receptor status during hypocaloric intake do not predict changes in adipocyte size or body shape. Metabolism 39:307–315, 1990Google Scholar
  11. 11.
    Kühl UG, Buschmann G: Cardiovascular profile of KC 8857 in comparison with other cardioactive agents. J Mol Cell Cardiol 19 (suppl III):50, 1987Google Scholar
  12. 12.
    Grohs JG, Fischer G, Raberger G: Cardiac and hemodynamic effects of the selective bradycardic agent KC 8857 during exerciseinduced myocardial ischemia. Eur J Pharmacol 161:53–60, 1989Google Scholar
  13. 13.
    Harris RA, Crabb DW: Metabolic interrelationships. In: TM Devlin (ed.) Textbook of Biochemistry. John Wiley, London, 1986, pp 531–557Google Scholar
  14. 14.
    Selby PL, Sherratt HSA: Substituted 2-oxiranecarboxylic acids: a new group of candidate hypoglycaemic drugs. Trends Pharmacol 10:495–500, 1989Google Scholar
  15. 15.
    Eistetter K, Wolf HPO: Etomoxir. Drugs of the Future 11:1034–1036, 1986Google Scholar
  16. 16.
    Wolf HPO: Aryl-substituted 2-oxirane carboxylic acids: A new group of antidiabetic drugs. In: CJ Bailey, PR Flatt (eds) New Antidiabetic Drugs. Smith-Gordon, London, 1990, pp 217–229Google Scholar
  17. 17.
    Agius L, Alberti KG: Regulation of flux through pyruvate dehydrogenase and pyruvate carboxylase in rat hepatocytes. Effects of fatty acids and glucagon. Eur J Biochem 152:699–707, 1985Google Scholar
  18. 18.
    Vaartjes WJ, De Haas CGM, Haagsman HP: Effects of sodium 2-[5-(4-chlorophenyl)-pentyl]-oxirane-2-carboxylate (POCA) on intermediary metabolism in isolated rat liver cells. Biochem Pharmacol 35:4267–4272, 1986Google Scholar
  19. 19.
    Lee SM, Bahl JJ, Bressler R: Prevention of the metabolic effects of 2-tetradecylglycidate by octanoic acid in the genetically diabetic mouse (db/db). Biochem Med 33:104–109, 1985Google Scholar
  20. 20.
    Tornvall P, Walldius G: A comparison between nicotinic acid and acipimox in hypertriglyceridaemia—effects on serum lipids, lipoproteins, glucose tolerance and tolerability. J Internal Med 230: 415–421, 1991Google Scholar
  21. 21.
    Rupp H, Dietz K: Mathematical models of myosin heterodimer formation in the rat heart during thyroid hormone alterations. Circ Res 68:27–37, 1991Google Scholar
  22. 22.
    Bauer JD: Clinical Laboratory Methods. C. V. Mosby, St. Louis, 1982, pp 554–555Google Scholar
  23. 23.
    Rupp H, Berger HJ, Pfeifer A, Werdan K: Effect of positive inotropic agents on myosin isozyme population and mechanical activity of cultured rat heart myocytes. Circ Res 68:1164–1173, 1991Google Scholar
  24. 24.
    Gupta MP, Gupta M, Stewar A, Zak R: Activation of alpha-myosin heavy chain gene expression by cAMP in cultured fetal rat heart myocytes. Biochem Biophys Res Commun 174:1196–1203 1991Google Scholar
  25. 25.
    Rösen P, Schmitz FJ, Reinauer H: Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyltransferase inhibitor etomoxir. In: M Nagano, S Mochizuki, NS Dhalla (eds) Cardiovascular Disease in Diabetes. Kluwer Academic Publ, Boston, 1992, pp 361–372Google Scholar
  26. 26.
    Reavan GM, Chang H, Hoffman BB: Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozotocin-induced diabetes. Diabetes 37:28–32, 1988Google Scholar
  27. 27.
    Leveille GA, Pardini RS, Tillotson JA: Influence of mediumchain triglycerides on lipid metabolism in the rat. Lipids 2:287–294, 1967Google Scholar
  28. 28.
    Doursout M-F, Kashimoto S, Chelly JE: Cardiac function in the diabetic conscious rat. In: M Nagano, NS Dhalla (eds) The Diabetic Heart. Raven Press, New York, 1991, pp 11–19Google Scholar
  29. 29.
    Heyliger CE, Pierce GN, Singal PK, Beamish RE, Dhalla NS: Cardiac alpha- and beta-adrenergic receptor alterations in diabetic cardiomyopathy. Basic Res Cardiol 77:610–618, 1982Google Scholar
  30. 30.
    Dillmann WH: Methyl palmoxirate increases Ca2+-myosin ATPase activity and changes myosin isoenzyme distribution in the diabetic rat heart. Am J Physiol 248:E602-E606, 1985Google Scholar
  31. 31.
    Morkin E, Flink IL, Goldman S: Biochemical and physiologic effects of thyroid hormone on cardiac performance. Progr Cardiovasc Disease 25:435–464, 1983Google Scholar
  32. 32.
    Randle PJ, Tubbs PK: Carbohydrate and fatty acid metabolism. In: RM Berne (ed.) Handbook of Physiology Section 2: The Cardiovascular System, Volume I. The Heart, American Physiological Society, Bethesda, 1979, pp 805–844Google Scholar
  33. 33.
    Weiss RG, Chacko VP, Gerstenblith G: Fatty acid regulation of glucose metabolism in the intact beating rat heart assessed by carbon-13 NMR spectroscopy: the critical role of pyruvate dehydrogenase. J Mol Cell Cardiol 21:469–478, 1989Google Scholar
  34. 34.
    Neely JR, Morgan HE: Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Ann Rev Physiol 36:413–459, 1974Google Scholar
  35. 35.
    Morris GS, Surdyka DG, Haddad F, Baldwin KM: Apparent influence of metabolism on cardiac isomyosin profile of food-restricted rats. Am J Physiol 258:R346-R351, 1990Google Scholar
  36. 36.
    Rupp H, Elimban V, Dhalla NS: Sucrose feeding prevents changes in myosin isoenzymes and sarcoplasmic reticulum Ca2+-pump ATPase in pressure-loaded rat heart. Biochem Biophys Res Commun 156:917–923, 1988Google Scholar
  37. 37.
    Rupp H, Elimban V, Dhalla NS: Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor. FASEB J 6:2349–2353, 1992aGoogle Scholar
  38. 38.
    Rupp H, Wahl R, Hansen M: Influence of diet and carnitine palmitoyltransferase I inhibition on myosin and sarcoplasmic reticulum. J Appl Physiol 72:352–360, 1992bGoogle Scholar
  39. 39.
    Dillmann WH: Diabetes-induced changes in specific proteins and mRNAs in the rat heart. In: M Nagano, NS Dhalla (eds) The Diabetic Heart. Raven Press, New York, 1991, pp 263–270Google Scholar
  40. 40.
    Russ M, Reinauer H, Eckel J: Diabetes-induced decrease in the mRNA coding for sarcoplasmic reticulum Ca2+-ATPase in adult rat cardiomyocytes. Biochem Biophys Res Commun 178:906–912, 1991Google Scholar
  41. 41.
    Rodrigues B, Goyal RK, McNeill JH: Effects of hydralazine on streptozotocin-induced diabetic rats: prevention of hyperlipidemia and improvement in cardiac function. J Pharmacol Exp Ther 237:292–299, 1986Google Scholar
  42. 42.
    Castelli WP: The triglyceride issue: a view from Framingham. Am Heart J 112:432–437, 1986Google Scholar
  43. 43.
    Rupp H: Insulin resistance, hyperinsulinemia, and cardiovascular disease. The need for novel dietary prevention strategies. Basic Res Cardiol 87:99–105, 1992Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Heinz Rupp
    • 1
    • 2
  • Vijayan Elimban
    • 1
    • 2
  • Naranjan S. Dhalla
    • 1
    • 2
  1. 1.Division of Cardiovascular SciencesSt. Boniface General Hospital Research CentreWinnipegCanada
  2. 2.Department of Physiology, Faculty of MedicineUniversity of ManitobaWinnipegCanada

Personalised recommendations